Vanguard Group Inc Summit Therapeutics Inc. Transaction History
Vanguard Group Inc
- $5.37 Trillion
- Q1 2025
A detailed history of Vanguard Group Inc transactions in Summit Therapeutics Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 11,640,507 shares of SMMT stock, worth $325 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
11,640,507
Previous 11,670,576
0.26%
Holding current value
$325 Million
Previous $208 Million
7.79%
% of portfolio
0.0%
Previous 0.0%
Shares
15 transactions
Others Institutions Holding SMMT
# of Institutions
238Shares Held
87.3MCall Options Held
1.77MPut Options Held
2.48M-
Baker Bros. Advisors LP New York, NY24.4MShares$681 Million5.62% of portfolio
-
Black Rock Inc. New York, NY7.9MShares$220 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD6.56MShares$183 Million0.02% of portfolio
-
State Street Corp Boston, MA4.85MShares$135 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA3.28MShares$91.6 Million0.01% of portfolio
About Summit Therapeutics Inc.
- Ticker SMMT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 201,215,008
- Market Cap $5.61B
- Description
- Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecu...